You are viewing: Italy AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The Italy AI in Life Science Market was valued at $598.1 Million in 2026 and projected to reach to $1943.4 Million by 2031, representing a compound annual growth rate of 26.6%. Italy's AI in Life Science market is poised for exceptional growth through 2031, driven by increasing investments in healthcare digitalization and pharmaceutical innovation.

Italy AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 26.6%, reflecting Italy's increasing adoption of artificial intelligence technologies across pharmaceutical research, diagnostics, and clinical applications.
  • Italy's healthcare sector is leveraging AI-driven solutions to enhance drug discovery, improve patient outcomes, and optimize operational efficiency across life science organizations. The Italian market benefits from strong government support for digital health initiatives and significant investment in research infrastructure.
  • Italy's position within the European Union provides access to collaborative networks and regulatory frameworks that facilitate AI innovation in life sciences.
  • By 2031, Italy is expected to establish itself as a key hub for AI-enabled life science applications, driven by partnerships between academic institutions, pharmaceutical companies, and technology providers focused on advancing precision medicine and personalized healthcare solutions..

Key Market Statistics

  • CAGR (2026-2031) 26.6% CAGR
  • Market Size, 2026 ~USD 598.1 Million
  • Forecast, 2031 ~USD 1943.4 Million
  • Country Italy

Italy AI in Life Science Market Overview

Strong Market Growth :

Italy's AI in Life Science market is expanding at 26.6% CAGR, outpacing the global average of 26.3%, demonstrating accelerated adoption of AI technologies within the Italian healthcare ecosystem.

Significant Market Expansion :

The market is projected to grow from $598.1 million in 2026 to $1,943.4 million by 2031, representing a 225% increase over five years and reflecting substantial investment in AI-driven pharmaceutical and diagnostic solutions.

Healthcare Innovation Hub :

Italy's pharmaceutical research sector and clinical institutions are increasingly integrating AI for drug discovery, personalized medicine, and diagnostic imaging, positioning the country as a growing innovation center in Southern Europe.

Digital Health Transformation :

Italian healthcare providers are leveraging AI technologies to enhance clinical decision-making, optimize patient outcomes, and streamline research operations, supported by government initiatives promoting digital health adoption.

Italy AI in Life Science Market Dynamics

  • Italian research institutions and healthcare providers are rapidly adopting AI solutions for drug development, diagnostic imaging, and personalized treatment approaches.
  • The market's 26.6% CAGR reflects strong momentum in integrating machine learning and AI analytics across clinical and research settings. Government support for digital health infrastructure and EU funding initiatives are accelerating AI adoption in Italy's life sciences sector.
  • Pharmaceutical companies and biotech firms are expanding AI capabilities for clinical trials and drug discovery, while hospitals are implementing AI-powered diagnostic tools.
  • This convergence of regulatory support, technological advancement, and healthcare demand positions Italy as a key growth market for AI in life sciences within the European region..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • Italy's AI in Life Science market will grow from $598.1M (2026) to $1,943.4M (2031) at a 26.6% CAGR.
    • Italy is leveraging AI for drug discovery, diagnostics, and clinical optimization across its healthcare ecosystem.
    • Italy's EU membership and government digital health initiatives create favorable conditions for AI adoption in life sciences.
    • Italy's market is positioned to become a significant European hub for AI-enabled precision medicine and personalized healthcare by 2031.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    Italy AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES23.228.736.346.25873.692.8115.726.1
    BIOTECHNOLOGY COMPANIES87.2108.8138.5177.2224.1286.2363.1455.526.9
    CRO & CDMO66.882.9104.9133.5167.9213.3269.1335.726.2
    DIAGNOSTIC COMPANIES4252.366.484.8107136.3172.7216.226.6
    OTHER END USERS10.412.816.120.325.231.739.648.824.9
    PHARMACEUTICAL COMPANIES149185.7236301.6381485.9615.8771.526.7
    TOTAL378.6471.2598.1763.5963.4122715531943.426.6

    Target Audience

    • Pharmaceutical Companies : Italian and international pharma firms need market intelligence to assess AI investment opportunities, identify acquisition targets, and develop localized AI-driven drug discovery and clinical trial solutions for the Italian market.
    • Healthcare Technology Providers : MedTech and software companies require Italy-specific data to evaluate market demand for AI diagnostics, clinical decision support systems, and healthcare analytics platforms tailored to Italian healthcare institutions.
    • Investment & Private Equity Firms : Investors seeking exposure to Italian life sciences need comprehensive market sizing, growth projections, and competitive analysis to identify promising AI healthcare startups and acquisition opportunities in Italy.
    • Healthcare Institutions & Hospitals : Italian hospitals and research centers need market insights to benchmark AI adoption rates, evaluate technology vendors, and justify investments in AI-powered diagnostics and clinical applications.
    • Government & Policy Makers : Italian health authorities and EU policymakers require market data to inform digital health strategy, allocate funding for AI infrastructure, and develop regulatory frameworks supporting life sciences innovation.

    Key Companies in the Italy AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise market valuations for Italy ($598.1M in 2026, $1,943.4M in 2031) with detailed CAGR analysis to benchmark investments and identify growth opportunities specific to the Italian market.
    • Competitive Landscape Intelligence : Understand Italy's unique competitive dynamics, key players in pharmaceutical AI, diagnostic technology providers, and emerging startups to inform market entry strategies and partnership decisions.
    • Sector-Specific Insights : Gain detailed analysis of AI applications across Italian pharmaceutical research, clinical diagnostics, personalized medicine, and drug discovery to identify high-potential investment and expansion areas.
    • Regulatory & Policy Context : Understand Italy-specific healthcare regulations, EU compliance requirements, government digital health initiatives, and reimbursement frameworks affecting AI adoption and market development.
    • Strategic Decision Support : Make informed decisions on market entry, product localization, partnership development, and resource allocation with Italy-focused forecasts and trend analysis through 2031.

    Frequently asked questions

    What is the current size of Italy's AI in Life Science market?

    Italy's AI in Life Science market is valued at $598.1 million in 2026, with expectations to reach $1,943.4 million by 2031.

    What is the growth rate for AI in Life Science in Italy?

    Italy's AI in Life Science market is projected to grow at a compound annual growth rate (CAGR) of 26.6% from 2026 to 2031.

    Which applications of AI are driving growth in Italy's life science sector?

    Italy's market growth is driven by AI applications in drug discovery, diagnostic imaging, clinical decision support, and personalized medicine optimization.

    How does Italy's market compare to other European countries?

    Italy represents a significant segment of the European AI in Life Science market, with strong growth momentum supported by government initiatives and research infrastructure investments.

    What factors are supporting AI adoption in Italy's life science industry?

    Italy's AI adoption is supported by EU regulatory frameworks, government digital health programs, academic-industry partnerships, and increasing investment in healthcare technology infrastructure.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status